No Data
No Data
Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
Notable Healthcare Headlines for the Week: Eli Lilly, Merck and Becton, Dickinson in Focus
The FDA has approved the small molecule therapy from Pfizer (PFE.US) / AbbVie (ABBV.US).
AbbVie (ABBV.US) announced that the USA FDA has approved the company's Emblaveo (aztreonam and avibactam) developed in conjunction with Pfizer (PFE.US) for market release, to be used in combination with metronidazole, to treat patients aged 18 and above with complicated intra-abdominal infections (cIAI), including infections caused by various resistant Gram-negative bacteria.
The USA FDA has approved the AbbVie-Pfizer medication for treating intra-abdominal infections.
On February 8, Glonghui reported that AbbVie announced on Friday that the USA Food and Drug Administration approved its drug for the treatment of complicated intra-abdominal infections (including those caused by resistant bacteria). AbbVie and its co-developer Pfizer's drug Emblaveo has been approved for use in combination with antibiotic medications for the treatment of such infections in patients aged 18 and older. In the USA, approximately 3.5 million people are affected by intra-abdominal infections (IAIs) each year, which can cause symptoms such as abdominal pain, fever, nausea, and vomiting. Emblaveo was approved in Europe last April and is set to launch in the USA in the third quarter of 2025.
AbbVie Says FDA Approves Emblaveo Antibiotic to Treat Abdominal Infections
Express News | Abbvie Inc - Emblaveo Available in U.S. in Q3 2025